Arctic Blue Beverages Wins Big Again in San Francisco – “A Superior Result”
Products of the Finnish beverage company Arctic Blue Beverages succeeded nobly at the prestigious The San Francisco World Spirit Competition (SFWSC). The company's newest gins, Arctic Blue Legacy Gin and Arctic Blue Gin Rose, won double gold. Silver was awarded to the innovative oat liqueur, Arctic Blue Oat.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005706/en/
“Although we know our products rank high in taste and quality globally, this was still an overwhelming result, for a relatively small player in the global alcohol industry,” Valtteri Eroma (left), the CEO of Arctic Blue Beverages, rejoices and adds: “Developing new products is always a team effort, but the key role in the taste of Arctic Blue products plays our internationally awarded Master Distiller Asko Ryynänen (right)." (Photo: Business Wire)
“Although we know our products rank high in taste and quality globally, this was still an overwhelming result, for a relatively small player in the global alcohol industry,” Valtteri Eroma, the CEO of Arctic Blue Beverages, rejoices.
“Developing new products is always a team effort, but the key role in the taste of Arctic Blue products plays our internationally awarded Master Distiller Asko Ryynänen. With Asko, we have developed an agile process to turn ideas effectively into award-winning products, which is now paying off,” Valtteri adds.
Arctic Blue Legacy is a barrel-aged gin sold in a unique bottle designed by Timo Sarpaneva. The product is targeted to the ultra-premium category and packed in a prestige handmade wooden gift package. It has already received the highest recognition at the International Wine and Spirit Competition (IWSC) with a gold medal and 95 points back in 2021.
Arctic Blue Gin Rose is the company's entry into the fast-growing category of pink gins. The taste profile is similar to the multi-award winning Arctic Blue Gin with hints of cinnamon rose petals in both scent and taste. The beautiful red color comes from Finnish bilberries.
Arctic Blue Oat is the world’s first gin-based oat liqueur, which was launched a year ago. It was already awarded with a bronze medal at the International Wine and Spirit Competition (IWSC) in 2021.
“Based on our experience after previous awards, this will give a great boost to the sales of our new products as well as our current products like Arctic Blue Oat. Therefore, immediately after hearing the preliminary information, we have worked hard to increase the production capacity of our products at the distillery,” says Valtteri Eroma.
Products of Arctic Blue Beverages have previously been successful in the SFWSC competition. For example in 2019 Arctic Blue Navy Strength Gin won Double Gold and the Best in Show awards at the World Spirits Awards in San Francisco.
Awards for Arctic Blue Beverages in 2022:
DOUBLE GOLD MEDAL, Arctic Blue Gin Rose (Flavoured Gin Category)
DOUBLE GOLD MEDAL, Arctic Blue Legacy Gin (Barrel Aged Gin Category)
SILVER MEDAL, Arctic Blue Oat, Finland (Other Liqueurs Category)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005706/en/
Contact information
Valtteri Eroma
CEO & Head of Brand
+358 40 550 1343
valtteri.eroma@arcticbluebeverages.com
Anniina Nissinen
PR- & communications Agency Mellakka Helsinki
+358 400 380010
anniina.nissinen@mellakka.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom